ERCC2 and neoplasm: In this study, BRCA2 mutated tumors were, similar to ERCC2 mutated tumors, associated with high numbers of mutations in a SBS5 context, indicating that this mutational signature is an indicator of a DDR-deficient tumor that may be more sensitive to chemotherapy.